Biomarkers are characteristic biological properties that can be detected and measured in a variety of biological matrices in the human body, including the blood and tissue, to give an indication of whether there is a threat of disease, if a disease already exists, or how such a disease may develop in an individual case. Along the continuum from exposure to clinical disease and progression, exposure, internal dose, biologically effective dose, early biological effect, altered structure and/or function, clinical disease, and disease progression can potentially be observed and quantified using biomarkers. While the traditional discovery of biomarkers has been a slow process, the advent of molecular and genomic medicine has resulted in explosive growth in the discovery of new biomarkers. In this review, issues in evaluating biomarkers will be discussed and the biomarkers of environmental exposure, early biologic effect, and susceptibility identified and validated in epidemiological studies will be summarized. The spectrum of genomic approaches currently used to identify and apply biomarkers and strategies to validate genomic biomarkers will also be discussed.
Summary
Citations
Citations to this article as recorded by
Could 8-oxoguanine DNA glycosylase 1 Ser326Cys polymorphism be a biomarker of susceptibility in cancer? Bensu Karahalil, Ayşe Başak Engin, Erdem Coşkun Toxicology and Industrial Health.2014; 30(9): 814. CrossRef
Application of classic epidemiological studies and proteomics in research of occupational and environmental exposure to lead, cadmium and arsenic Barbara Kossowska, Ilona Dudka, Roman Gancarz, Jolanta Antonowicz-Juchniewicz International Journal of Hygiene and Environmental Health.2013; 216(1): 1. CrossRef
The vanishing zero revisited: Thresholds in the age of genomics Helmut Zarbl, Michael A. Gallo, James Glick, Ka Yee Yeung, Paul Vouros Chemico-Biological Interactions.2010; 184(1-2): 273. CrossRef